Genmab Shares Slide as It Shelves Zalutumumab
By Cormac Sheridan
Monday, June 27, 2011
Shares in Genmab A/S dropped 11 percent Friday on news that the company had failed to secure a deal for its epidermal growth factor receptor (EGFR) inhibitor zalutumumab and has opted to shelve the program.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.